340B Health

Johnson & Johnson has backed off its plan for now to impose #340B rebates for two of its most in-demand drugs. We appreciate the efforts of our member hospitals, the Health Resources and Services Administration (HRSAgov), HHS, and nearly 200 U.S. House lawmakers led by Rep. Abigail Spanberger who advocated against J&J’s plans. Replacing upfront discounts with rebates would upend 30+ years of 340B operations and result in major financial burdens on safety-net hospitals and harm to care for patients who rely on them. More: bit.ly/4drzR5N #Protect340B

U.S. Senators Peter Welch, Patty Murray, and Maria Cantwell recently wrote a letter expressing appreciation for the swift enforcement action the Health Resources and Services Administration (HRSAgov), HHS showed against Johnson & Johnson during the drugmaker's attempt to enact #340B rebates for two of its drugs. The senators also called on the agency to continue blocking any such attempts. Their letter states: “The legislative intent of 340B was to prevent companies from implementing a rebate model, like J&J attempted. We agree that the statute is clear on that point.” Read more below. #Protect340B Office of U.S. Senator Peter Welch

Excited for the 340B Roundtable here in Puyallup with 340B Health! #340b #340bhealth #pharmacy #roundtable #protect340b

Health care trends such as the increased use of costly specialty medicines for chronic conditions and shifts from the inpatient to the outpatient setting affect #340B. Read more about the 340B purchase numbers published recently by Health Resources and Services Administration (HRSAgov), HHS: bit.ly/3zXtJ7Z #Becauseof340B

“The 340B program allowed the hospital to make health care affordable.”   Listen to Richard Bey’s patient success story as he recounts being one day away from entering a coma when a San Mateo County Health resident informed him of #340B. Richard, suffering from an extreme case of anemia while battling a sleep disorder, qualified for one of the hospital’s patient support programs, which helped take care of his $30,000 medical bill. #Becauseof340B

Johnson & Johnson’s proposed rebate scheme and the strong enforcement response from Health Resources and Services Administration (HRSAgov), HHS was just the latest in a yearslong campaign by the pharmaceutical industry to fundamentally change #340B. We invited our Senior Counsel Amanda Nagrotsky on #340BInsight to discuss the saga and prepare us for future showdowns: bit.ly/3BqT8av #Protect340B

The decision of a federal judge in Louisiana will help ensure the continued partnership between safety-net providers and their community and specialty contract pharmacies. These agreements align with the intent of #340B—stretch scarce resources and serve more patients—and must be protected in the states and nationwide. #Protect340B 

Our President and CEO Maureen Testoni will discuss the pharmaceutical industry’s latest attempt to turn #340B discounts into rebates on RACmonitor. Tune in at 10 a.m. ET on the livestream below, or online: bit.ly/45bQBdV #Protect340B 

Why are pharmaceutical companies seeking to turn #340B discounts into rebates? We recently invited our President and CEO Maureen Testoni onto #340BInsight to discuss this, CMS’s IRA implementation guidance, litigation over pharmacy partnerships, and more. Listen and learn: bit.ly/3XCBn0j #Protect340B

A major drug company’s attempt to turn 340B drug pricing program discounts into rebates made big headlines in recent weeks. Maureen Testoni, president and CEO of 340B Health, will review how this potentially major upheaval came about, how 340B stakeholders responded, and how the drugmaker backed off after the federal government threatened it with massive penalties. This debate is by no means over. The idea of imposing rebates in 340B is not a new one, and the concept has come back into prominence recently amid the ongoing implementation of the Inflation Reduction Act, which will have important effects on 340B. Other segments during the weekly Internet broadcast will include these instantly recognizable features: •Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds. •The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors. •Legislative Update: Folana Houston, assistant general counsel for Zelis, will report on current healthcare legislation. •Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.